Lakefront Biotherapeutics NV
corporate_fare Company Profile
Lakefront Biotherapeutics NV (NASDAQ:GLPG) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 16 items for GLPG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-06, rated 9/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GLPG spans 6-K, 20-F.
Recent high-impact activity:
- Galapagos Reports Q1 Profit Turnaround, Details Major Gilead/Ouro Biotherapeutics Collaboration, and Strategic Pipeline Expansion
- Galapagos Q1 Results Detail Gilead Partnership for Autoimmune Drug, $1.675B Upfront Split
- Shareholders Approve Rebranding to Lakefront Biotherapeutics, 10% Share Buyback Authorization, and New Board Chair
- $500M Cash Pool, $150M Buyback Authorized for Galapagos in Binding Gilead Collaboration
- Galapagos Finalizes Binding Agreement with Gilead for Ouro Medicines' T-Cell Engager Program, Gains $500M Strategic Flexibility
Dilution Risk
Low riskFiling-implied dilution signals for GLPG, detected from its recent SEC filings · based on capital-structure filings through 2026-05-08.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
GLPG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.